scPharmaceuticals Inc. (SCPH) announced on Monday promising topline results from their pharmacokinetic study of SCP-111 (furosemide) delivered via an autoinjector.
The study assessed the bioavailability and pharmacokinetics, as well as the pharmacodynamics, of SCP-111 when administered subcutaneously through an autoinjector. This was compared to the FDA-approved intravenous (IV) injection of furoscix, used for at-home treatment of congestion caused by fluid overload in adults with chronic heart failure.
SCP-111 exhibited a bioavailability of 107.3 percent. Additionally, participants who received SCP-111 showed comparable urine output, urinary sodium excretion, and urinary potassium excretion to those who were administered IV furosemide.
scPharmaceuticals Inc. intends to file a supplemental new drug application with the FDA by the end of this year.
